Study of Low-dose Decitabine with COP Chemotherapy for Relapsed and Refractory Diffuse Large B-Cell Lymphoma in Adults

What this Trial Is About

Researchers are evaluating the use of low-dose decitabine combined with the COP chemotherapy regimen for patients with relapsed and refractory diffuse large B-cell lymphoma DLBCL. DLBCL is the most common type of non-Hodgkins lymphoma, and while the first-line R-CHOP chemotherapy improves remission rates, many patients face relapse and unsatisfactory long-term survival. Decitabine, a DNA methyltransferase inhibitor, has shown promise in treating other cancers by reversing DNA methylation and inducing tumor cell death, prompting this study to explore its effect combined with COP in DLBCL treatment. Participants receive the D-COP regimen chemotherapy, which combines low-dose decitabine with Cyclophosphamide, Vindesine, and Bonisone. This treatment is given in 4 to 6 courses. The study focuses on relapsed and refractory high-risk DLBCL patients, aiming to evaluate the efficacy and safety of this combined approach. The study is observational and open-label, with all enrolled participants receiving the D-COP treatment. During the study, participants will be monitored through assessments of measurable lesions, physical exams, and clinical evaluations. Researchers will track responses to treatment, including remission and survival outcomes, as well as safety and side effects. The study runs from March 1, 2018, to December 31, 2020, and aims to improve prognosis for patients with relapsed and refractory DLBCL while identifying which patient groups may benefit most from this therapy.

A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL